Prof. Dr. Birgit Luber
Academic Career and Research Areas
P rof. Luber works in the field of M olecular and T ranslational medicine and focuses on the identification and validation of predictive biomarkers in the context of targeted molecular therapies for gastric cancer. The research group's work focuses on molecular therapies against receptor tyrosine kinases (E GFR, HER2). She takes an interdisciplinary approach, collaborating with pathologists, oncologists, mathematicians and natural scientists. In this context, she coordinated the BMBF project SYS Stomach and was involved in the BMBF projects CANCERMOTISYS and MicMode I2T.
Prof. Luber studied technical chemistry at the Technische Hochschule Nürnberg Georg Simon Ohm (the (diploma, 1986) and biochemistry at the Fre ie Universität Berlin (diploma, 1990) and obtained h er doctorate in biochemistry (1994, Fre ie Universität Berlin ) after completing h er doctoral thesis at the Max Planck Institute for Biochemistry in Martinsried . This was followed by research visit s at the Necker Hospital in Paris, France (1994 1997) and at the Helmholtz Centre in Munich, Neuherberg (1997 2000). Since 2000, she has headed the Molecular and Translational Medicine working group at the Institute of Pathology at the Technical University of Munich, habilitated in experimental pathology at the TUM Faculty of Medicine (2004), received her teaching licence (2005) and was appointed adjunct professor (2011). She places particular emphasis on promoting young scientists. Her teaching and examination activities within interdisciplinary teams focus primarily on medicine and are also carried out in close cooperation with the TUM School of Life Sciences.
Key Publications (all publications)
Spatial Metabolomics Identifies Distinct Tumor Specific Subtypes in Gastric Cancer Patients.
Wang J, Kunzke T, Prade VM, Shen J, Buck A, Feuchtinger A, Haffner I, Luber B, Liu DHW, Langer R, Lordick F, Sun N, Walch A. Clin Cancer Res. 2022 Jul 1;28(13):2865 2877. doi: 10.1158/10780432.CCR 21 4383. PMID: 35395077
Combining gene expression analysis of gastric cancer cell lines and tumor specimens to identify biomarkers for anti HER therapies the role of HAS2, SHB and HBEGF.
Ebert K, Haffner I, Zwingenberger G, Keller S, Raimúndez E, Geffers R, Wirtz R, Barbaria E, Hollerieth V, Arnold R, Walch A, Hasenauer J, Maier D, Lordick F, Luber B. BMC Cancer. 2022 Mar 9;22(1):254. doi: 10.1186/s12885 022 09335 4. PMID: 35264144 Free PMC article.
HER2 Expression, Test Deviations, and Their Impact on Survival in Metastatic Gastric Cancer: Results From the Prospective Multicenter VARIANZ Study.
Haffner I, Schierle K, Raimúndez E, Geier B, Maier D, Hasenauer J, Luber B, Walch A, Kolbe K, Riera Knorrenschild J, Kretzschmar A, Rau B, Fischer von Weikersthal L, Ahlborn M, Siegler G, Fuxius S, Decker T, Wittekind C, Lordick F. J Clin Oncol. 2021 May 1;39(13):1468 1478. doi: 10.1200/JCO.20.02761. Epub 2021 Mar 25. PMID: 33764808 Free PMC article.
Determining the effects of trastuzumab, cetuximab and afatinib by phosphoprotein, gene expression and phenotypic analysis in gastric cancer cell lines.
Ebert K, Zwingenberger G, Barbaria E, Keller S, Heck C, Arnold R, Hollerieth V, Mattes J, Geffers R, Raimúndez E, Hasenauer J, Luber B. BMC Cancer. 2020 Oct 28;20(1):1039. doi: 10.1186/s12885 02007540 7. PMID: 33115415 Free PMC article.
Modelbased analysis of response and resistance factors of cetuximab treatment in gastric cancer celllines.
Raimúndez E, Keller S, Zwingenberger G, Ebert K, Hug S, Theis FJ, Maier D, Luber B, Hasenauer J. PLoS Comput Biol. 2020 Mar 2;16(3):e1007147. doi: 10.1371/journal.pcbi.1007147. eCollection 2020 Mar. PMID: 32119655 Free PMC article.
If you wish your profile to be changed or updated please contact Franz Langer.